Zenith Presentation at AACR Meeting April 10-15

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith Presentation at AACR Meeting April 10-15

posted on Apr 09, 2021 02:43PM

AACR Annual Meeting: April 10-15, 2021

1129 - Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status

https://www.abstractsonline.com/pp8/#!/9325/presentation/2286

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply